- PR Newswire•5 days agoLifshitz & Miller Law Firm Announces Investigation of Ally Financial Inc., Amphastar Pharmaceuticals, Inc., Lannett Company, Inc., Live Ventures Incorporated, MiMedx Group, Inc., Seattle Genetics, Inc., Teligent, Inc., TerraVia Holdings, Inc., and Zimmer Biomet Holdings, Inc.
NEW YORK, January 19, 2017 /PRNewswire/ -- Ally Financial Inc. (ALLY) Lifshitz & Miller announces investigation on behalf of ALLY investors concerning whether ALLY adequately disclosed information regarding ...
- Business Wire•10 days agoMIMEDX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of MiMedx Group, Inc. - MDXG
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into MiMedx Group, Inc.
- PR Newswire•15 days ago
MARIETTA, Ga., Jan. 9, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, today announced its record results for the fourth quarter and full year 2016. The Company recorded record revenue for the year ended December 31, 2016 of $246.8 million, a $59.5 million or 32% increase over 2015 revenue of $187.3 million. The Company recorded record revenue for the 2016 fourth quarter of $71.6 million, a $19.8 million or 38% increase over 2015 fourth quarter revenue of $51.8 million.
MDXG : Summary for MiMedx Group, Inc - Yahoo Finance
MiMedx Group, Inc. (MDXG)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||7.50 x 1000|
|Ask||8.99 x 700|
|Day's Range||7.97 - 8.19|
|52 Week Range||6.64 - 10.02|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||45.08|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|